ML264

Catalog No.S8196 Batch:S819602

Print

Technical Data

Formula

C17H21ClN2O4S
Molecular Weight 384.88 CAS No. 1550008-55-3
Solubility (25°C)* In vitro DMSO 200 mg/mL (519.64 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ML264 (CID-51003603), a selectively inhibitor of kruppel-like factor 5 (KLF5),potently Inhibits Growth of Colorectal Cancer.
Targets
KLF5 [1]
(Cell-based assay for proliferation of DLD-1 cells)
29 nM
In vitro ML264 potently halts DLD-1 viability (IC50 = 29 nM) with high maximal effect (>90%). DLD-1 cells are human colorectal adenocarcinoma cells. This compound has significant effects at submicromolar doses on other cell types as well, including HCT116 (human colorectal carcinoma), HT29 (human colorectal adenocarcinoma), and SW620 (human colorectal adenocarcinoma). The IEC-6 anti-target (a nontransformed rat intestinal epithelial cell line) is largely unaffected, with inhibition below 50% at the highest dose.This compound potently inhibits proliferation of CRC cells in vitro through modifications of the cell cycle profile.
In vivo In an established xenograft mouse model of colon cancer, ML264 efficiently inhibits growth of the tumor within five days of treatment. This effect is caused by a significant reduction in proliferation and that this compound potently inhibits the expression of KLF5 and EGR1, a transcriptional activator of KLF5.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    DLD-1 and HCT116 colorectal cancer cell lines

  • Concentrations

    10μM

  • Incubation Time

    24, 48, 72h

  • Method

    For cell proliferation experiments, DLD-1 and HCT116 cells are treated with 10μM ML264 or with vehicle (DMSO). Live cells are collected at 24, 48 and 72 hours post treatment and their numbers are determined by counting using a Coulter counter; In MTS assay, DLD-1 and HCT116 cells are treated with 10μM this compound or with vehicle (DMSO). After 24, 48, and 72 hours of incubations, 20 μL of MTS solution  is added to each well and an analysis is performed according to the manufacturer's protocol.
Animal Study:

[2]
  • Animal Models

    Nude mice with DLD-1 cells injection to achieve a tumor

  • Dosages

    10 or 25 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/23762940/
  • https://pubmed.ncbi.nlm.nih.gov/26621868/

Selleck's ML264 Has Been Cited by 17 Publications

Krüppel-like factor 5 promotes the progression of oral squamous cell carcinoma via the baculoviral IAP repeat containing 5 gene [ Annals of Translational Medicine, September 2022, 969] PubMed: 36267746
Histone methyltransferase GLP epigenetically activates GPCPD1 to sustain cancer cell metastasis and invasion [ Genome Instability & Disease, September 2022, 21-37]
Demethylation of G-Protein-Coupled Receptor 151 Promoter Facilitates the Binding of Krüppel-Like Factor 5 and Enhances Neuropathic Pain after Nerve Injury in Mice [ Journal of Neuroscience, December 5, 2018, 10535-10551] PubMed: 30373770
Demethylation of G-Protein-Coupled Receptor 151 Promoter Facilitates the Binding of Krüppel-Like Factor 5 and Enhances Neuropathic Pain after Nerve Injury in Mice [ Journal of Neuroscience, December 05, 2018, 10535-10551] PubMed: 30373770
Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting [ Journal of Translational Medicine, April 30, 2025, 492] PubMed: 40307891
KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency [ Nat Commun, 2025, 16(1):480] PubMed: 39779698
Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting [ J Transl Med, 2025, 23(1):492] PubMed: 40307891
Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting [ Journal of Translational Medicine, 2025, 492] PubMed: 40307891
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma [ Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9] PubMed: 39658630
Histone methyltransferase GLP epigenetically activatesGPCPD1to sustain cancer cell metastasis and invasion [ Genome Instability & Disease, 2023, 4, 21–37] PubMed: None

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.